Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,577 matching trials from the local directory fallback.
Filters: Intervention: therapy Clear all
Active, not recruiting Phase 3 Interventional

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine + S-1, Gemcitabine + carboplatin, Gemcitabine + cisplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Gemcitabine + oxaliplatin, Gemcitabine monotherapy
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial Evaluating Elimination of Radiation Therapy

NCT00593840
View directory record Official record
Conditions
Cancer of the Larynx
Interventions
Intensity modulated radiation therapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 8:15 AM EDT
Active, not recruiting Phase 1 Interventional

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT06710223
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Cryotherapy, Durvalumab, SD-101, Tremelimumab
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 6:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

NCT05044546
View directory record Official record
Conditions
Depression, Tobacco Use Disorder
Interventions
Behavioral Activation Therapy, Discussion, Health Education, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 6, 2026, 3:35 PM EDT
Active, not recruiting Phase 2 Interventional

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT03180502
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 10:27 AM EDT
Active, not recruiting Not applicable Interventional

Dynamic Deconstructive Psychotherapy Versus Brief Intervention and Contact for Suicidal Adolescents and Young Adults

NCT05988489
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Brief Intervention and Contact (BIC), Dynamic Deconstructive Psychotherapy (DDP)
Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
14 Years to 40 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Aug 4, 2026, 2:26 AM EDT
Active, not recruiting Not applicable Interventional

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

NCT06295744
View directory record Official record
Conditions
Early-stage Breast Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 3:15 AM EDT
Active, not recruiting Phase 1 Interventional

Ultra-fractionated Radiotherapy for Rectal Cancer

NCT04677413
View directory record Official record
Conditions
Rectal Cancer
Interventions
Ultrafractionated radiotherapy for rectal cancer
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 15, 2026, 8:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014
View directory record Official record
Conditions
Bladder Cancer, Head/Neck Cancers, Lung Cancer, Melanoma Cancer, Metastatic Cancer, Renal Cancer
Interventions
Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab, Stereotactic Body Radiotherapy
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 3, 2026, 8:04 PM EDT
Active, not recruiting Phase 2 Interventional

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

NCT03456843
View directory record Official record
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 15, 2026, 4:31 PM EDT
Active, not recruiting Phase 1 Interventional

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib, Administration of ceralasertib and durvalumab, Administration of ceralasertib and olaparib, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin, Administration of ceralasertib in combination with olaparib, Administration of ceralasertib monotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 5:28 PM EDT
Active, not recruiting No phase listed Observational

Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

NCT07313384
View directory record Official record
Conditions
Obesity (Disorder), Obesity Type 2 Diabetes Mellitus
Interventions
GLP-1 Therapy
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Columbia, South Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 28, 2026, 11:39 AM EDT
Active, not recruiting No phase listed Observational

IORT-Breast at Medical Center Navicent Health

NCT04595435
View directory record Official record
Conditions
Breast Cancer Female, Early-stage Breast Cancer
Interventions
Intraoperative Radiation Therapy, Lumpectomy
Radiation · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 15, 2026, 8:05 PM EDT
Active, not recruiting Not applicable Interventional

Accelerated Treatment of Endocarditis

NCT03851575
View directory record Official record
Conditions
Infectious Endocarditis
Interventions
Accelerated treatment of endocarditis, Usual guideline therapy
Other
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Other
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 10:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290
View directory record Official record
Conditions
Advanced Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, Metastatic Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, NSCLC, Non-Small Cell Lung Cancer
Interventions
silevertinib (BDTX-1535) monotherapy
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 13, 2026, 8:59 PM EDT
Active, not recruiting No phase listed Observational

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

NCT01352429
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
IMRT, Proton Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 1:48 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Trifecta Research Study

NCT07717866
View directory record Official record
Conditions
Brain Injury, Cognitive Dysfunction, Depression - Major Depressive Disorder, PTSD - Post Traumatic Stress Disorder, Suicidal Ideation
Interventions
5-methoxy-N,N-dimethyltryptamine, Ibogaine Hydrochloride with Magnesium Sulfate, Magnetic e-Resonance Therapy (MeRT), Physiological Supplementation
Drug · Device
Lead sponsor
Axial Therapeutic Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 28, 2026, 1:07 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy

NCT05631236
View directory record Official record
Conditions
Veteran Aged 65 and Older
Interventions
Bright Light Therapy (AYO Glasses)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Aug 20, 2026, 7:49 PM EDT
Active, not recruiting No phase listed Observational

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

NCT04447651
View directory record Official record
Conditions
Metastatic Solid Tumor, SF3B1 Gene Mutation, SRSF2 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation
Interventions
Recommendation for treatment with immunotherapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 31, 2026, 4:34 AM EDT
Active, not recruiting No phase listed Observational

Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype

NCT05742360
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
CPAP therapy
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 15, 2026, 4:31 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
External beam radiation therapy, Ferumoxytol injection, Pharmacological ascorbate, Temozolomide
Radiation · Drug
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 29, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

NCT03704662
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Preoperative Fractionated Radiation Therapy and Chemotherapy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 29, 2026, 10:28 PM EDT
Active, not recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Sep 7, 2026, 5:30 PM EDT
Active, not recruiting Phase 2 Interventional

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
Interventions
Durvalumab, Internal Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 15, 2026, 10:51 AM EDT